arrow
V

Valter Torri

vita-salute san raffaele university
H指数:92
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial

可切除和临界可切除胰腺导管腺癌的短期与长期新辅助化疗比较(PACT-21 CASSANDRA):一项随机、开放标签、2×2析因设计的III期试验第二次随机化分析结果

2026-09-010
OAAI
Surgical volume, structural quality, and compliance with European Society of Gynaecological Oncology quality indicators in endometrial and cervical cancer: a regional cross-sectional assessment

手术量、结构性质量以及子宫内膜癌和宫颈癌患者对欧洲妇科肿瘤学会质量指标的依从性:一项区域性横断面评估

2026-07-010
PRE
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis

免疫疗法在晚期非小细胞肺癌III期试验中,ORR与PFS与OS结局的相关性:系统评价与Meta分析

2025-12-160
OAAI
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma

一项关于术前化疗联合mFOLFIRINOX或PAXG方案治疗I-III期胰腺导管腺癌的随机III期试验结果

2025-10-310
PRE
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis

铂类化疗和CTLA-4抑制对非小细胞肺癌中一线抗PD-1/PD-L1药物获得性耐药的影响:一项系统综述和重构的个体患者数据分析

2025-09-020
PREAI
Rationale and design of the AUSTRAL trial: An open-label, multicenter, phase II study evaluating radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in stage III NSCLC patients with thoracic relapses and/or oligometastases after the PACIFIC regimen.

AUSTRAL试验的原理与设计:一项开放标签、多中心、II期研究,旨在评估在完成PACIFIC方案治疗后出现胸腔内复发和/或寡转移的III期NSCLC患者中,采用放疗后序贯度鲁瓦木单抗(MEDI4736)和塞拉拉塞替(AZD6738)的治疗效果。

2025-07-120
PRE
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis

新辅助与围手术期化免疫疗法根据病理反应在可切除非小细胞肺癌中的比较:一项重构的个体患者数据meta分析

2025-06-011
PRE
Mepitel® film versus standard care for the prevention of skin toxicity in breast cancer patients treated with adjuvant radiotherapy: A randomized controlled trial

Mepitel®薄膜与标准护理在预防接受辅助放疗的乳腺癌患者皮肤毒性方面的比较:一项随机对照试验

2025-05-010
OAAI
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
2023-12-0110
PRE
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies

肿瘤浸润淋巴细胞与激素受体阳性/HER2-negative乳腺癌复发评分的关系: 四项前瞻性研究分析

2023-12-013
OA
A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study
2023-07-0114
OAAI
Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial)
2023-06-016
OAAI